Study wrapper · #1353
Oral Incretin-Based Therapies for Weight Management.
Cheng HE, Bonafede M, Shukla AP Current atherosclerosis reports. 2026.
DOI: 10.1007/s11883-026-01456-6PubMed: 42696191
Editor's note
A narrative review tracking the shift from injectables to oral incretin formulations, a shift with obvious implications for access and adherence. The efficacy figures quoted match the phase 3 record, and the authors flag a real safety watchpoint: drug-induced liver injury seen with first-generation small-molecule agents. No new data, but a solid map of a fast-moving pipeline.
Plain-language abstract
This review covers pill-based incretin drugs for weight management, led by the two FDA-approved options — oral semaglutide and orforglipron — which each produced more than 10% weight loss in phase 3 trials with side effects typical of the GLP-1 class.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026